Entrada Therapeutics Receives EU Authorization to Start Exon 45 Skipping Clinical Trial in Duchenne Muscular Dystrophy
Entrada Therapeutics, today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial...
Entos Pharmaceuticals Develops Re-Dosable, Full-Length Dystrophin Gene Therapy: Fusogenix PLV Method
Entos Pharmaceuticals Inc. (Entos) is a biotech business that creates genetic therapies using its non-viral, redosable Fusogenix PLV delivery technology. CureDuchenne Ventures announced an...
Genethon Reports Results of GNT0004 Gene Therapy Clinical Trial: Permanent Decrease in CK Levels of More Than 75%
Safety, efficacy, and pharmacodynamic results show good tolerance of GNT0004 associated with transient immunological prophylactic treatment, as well as efficacy data in terms of...
Precision BioSciences PBGENE-DMD Restores Production of Nearly Full-Length Dystrophin Protein
Precision BioSciences, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company’s first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD).
What...
Satellos Reports SAT-3247 Q1 2025 Results, Highlights Recent Company Progress and Future Plans
Satellos Bioscience, today announced its financial results and corporate highlights for the first quarter ended March 31, 2025.
“We are very pleased with our continued...